The eVOLVE-Lung02 trial was testing whether volrustomig plus chemotherapy could improve outcomes over the established combination of pembrolizumab and chemotherapy in previously untreated patients with metastatic NSCLC and low PD-L1 expression.<\/p>\n
An Independent Data Monitoring Committee (IDMC) recommended stopping the trial after a planned review found that the experimental regimen was unlikely to demonstrate a benefit in either of the study\u2019s dual primary endpoints: progression-free survival (PFS) or overall survival (OS). The assessment focused on the primary analysis population of patients whose tumors were PD-L1 negative, with expression below 1%.<\/p>\n
No new safety signals were identified. AstraZeneca said the safety profile of volrustomig plus chemotherapy remained consistent with the known profiles of the individual treatments.<\/p>\n
The drug behind the trial<\/p>\n
Volrustomig is a bispecific antibody designed to block two immune checkpoints, PD-1 and CTLA-4, on the same T cell. The rationale is to combine two mechanisms of immune activation in an effort to generate a stronger and more durable anti-tumor response.<\/p>\n
The concept is particularly relevant in tumors with low PD-L1 expression, where established PD-1\/PD-L1 immunotherapies can deliver less durable responses.<\/p>\n
The global, randomized, open-label eVOLVE-Lung02 trial enrolled 895 patients across 25 countries. Patients received either intravenous volrustomig at 750 mg plus chemotherapy or pembrolizumab at 200 mg plus chemotherapy.<\/p>\n
A setback within a broader pipeline<\/p>\n
The discontinuation is significant because lung cancer is one of the key battlegrounds for AstraZeneca\u2019s oncology business. NSCLC accounts for roughly 80\u201385% of lung cancers, and many patients are diagnosed only after the disease has metastasized.<\/p>\n
For AstraZeneca, however, the volrustomig result is not an isolated development setback. The company has recently faced a series of disappointments across its pipeline, including the late-stage failure of cardiovascular drug Wainua, U.S. regulatory difficulties for breast cancer candidate camizestrant and a trial setback for Ultomiris in a rare disease.<\/p>\n
The cumulative setbacks have put additional focus on AstraZeneca\u2019s ability to replenish its pipeline and deliver the growth targets underpinning its long-term strategy. The company continues to target $80 billion in annual revenue by 2030, a goal that depends heavily on successful launches of new medicines.<\/p>\n
At the same time, Monday brought positive news from AstraZeneca\u2019s oncology pipeline. Two other late-stage lung cancer studies \u2013 involving the Tagrisso\/Orpathys combination and Enhertu, developed with Daiichi Sankyo \u2013 met their primary endpoints.<\/p>\n
What happens next?<\/p>\n
AstraZeneca will work with investigators to ensure continued care and follow-up for patients enrolled in eVOLVE-Lung02. The company said other Phase III studies of volrustomig will continue, including trials in cervical cancer, head and neck squamous cell carcinoma and mesothelioma.<\/p>\n
For AstraZeneca, the immediate question is therefore not whether volrustomig has failed as a platform, but where its dual-checkpoint approach can deliver a meaningful clinical advantage. The lung cancer result suggests that the strategy has not so far translated into sufficient benefit in this particular first-line setting \u2013 raising the stakes for the remaining Phase III program.<\/p>\n","protected":false},"excerpt":{"rendered":"The eVOLVE-Lung02 trial was testing whether volrustomig plus chemotherapy could improve outcomes over the established combination of pembrolizumab…\n","protected":false},"author":2,"featured_media":106491,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,44028,1852,44342,44343,28913,29793,43830],"class_list":["post-106490","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-bispecific","tag-cancer","tag-checkpoint","tag-ctla-4","tag-lung-cancer","tag-nsclc","tag-pd-1"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117121336182987015","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/106490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=106490"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/106490\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/106491"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=106490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=106490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=106490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}